ArticleSurgery2018
Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease?
Article in Surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 101 citations in OpenAlex.
- Risk stratification for reoperation outcomes in recurrent or persistent papillary thyroid carcinoma: development and validation of a machine learning model.BMC medical informatics and decision making · 2026Article
- Horner syndrome after ethanol ablation for radioactive iodine therapy refractory papillary thyroid carcinoma.JCEM case reports · 2026Article
- Prognostic Comparison of Long-Term Outcomes and Nodal Recurrence for Persistent and Recurrent Differentiated Thyroid Cancer.Clinical and experimental otorhinolaryngology · 2026Article
- Highly sensitive profiling somatic mutations of thyroid cancer by nucleotide-enrichment-based MALDI-TOF MS assay.Scientific reports · 2026Article
- Combined Ultrasound and MRI Assessment in Patients Undergoing Reoperation for Recurrent Papillary Thyroid Carcinoma: Oncological Outcomes and Surgical Safety.Current oncology (Toronto, Ont.) · 2026Article
- Two-year dynamic risk stratification and adjuvant radioiodine efficacy in initial non-distant metastatic papillary thyroid carcinoma harboring TERT promoter mutations.Frontiers in oncology · 2026Article
- Thermal field management in thyroid ablation for papillary thyroid carcinoma: Advancing precision and patient-centered care.World journal of radiology · 2025Article
- Thermal ablation for papillary thyroid carcinoma in the isthmus: a systematic review and meta-analysis.Gland surgery · 2025Article
- Less is more: once vs. multiple radioactive iodine (RAI) therapy in patients with RAI-avid pulmonary micrometastatic differentiated thyroid cancer.European journal of nuclear medicine and molecular imaging · 2025Article
- Predictive factors for re-recurrence in papillary thyroid carcinoma following reoperation: a retrospective analysis.Gland surgery · 2025Article
- Clinical Risk Factor for Detected Distant Metastasis and Anaplastic Transformation After Reoperation in Recurrent/Persistent Differentiated Thyroid Cancer: A Retrospective Cohort Study.Laryngoscope investigative otolaryngology · 2025Article
- Age-related characteristics in differentiated thyroid cancer: a 20-year single-center retrospective analysis in pediatric and adolescent patients.Archives of endocrinology and metabolism · 2025Article
- Feasibility of Lobectomy in Selected Patients with Unilateral N1b Papillary Thyroid Cancer.Annals of surgical oncology · 2025Article
- Outcome analysis of differentiated thyroid cancer: Experience from tertiary care in Karachi.Pakistan journal of medical sciences · 2024Article
- LINC00261 triggers DNA damage via the miR-23a-3p/CELF2 axis to mitigate the malignant characteristics ofBiochemistry and biophysics reports · 2024Article
- Article
- Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.Nature communications · 2024Article
- Recurrent Middle Eastern Differentiated Thyroid Carcinoma Has Worse Outcomes Than Persistent Disease.Journal of clinical medicine · 2024Article
- Article
- TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort.Advances in therapy · 2024Article
Corrections and comments
- Commented on byDiscussion.2018
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundPapillary thyroid carcinoma has excellent survival, yet recurrence remains a challenge. We sought to determine the proportion of reoperations performed for persistent, rather than truly recurrent, disease.
methodsWe conducted a retrospective review of a prospectively maintained database. Patients with papillary thyroid carcinoma who underwent reoperation for disease from 2000-2016 were included. We defined recurrence as disease that developed after a patient had an undetectable thyroglobulin and a negative ultrasonography within 1 year of operation.
resultsA total of 69 patients underwent 92 reoperations. On initial pathology, mean tumor size was 2.6 cm, 51% were multifocal, and 42% had extrathyroidal extension. Half (46%) of the patients underwent a central/lateral neck dissection at the initial operation, and 77% were treated with postoperative radioactive iodine. The median time to first reoperation was 21 months (range, 1-292), and 42% occurred within 1 year. Only 3 operations met criteria for true "recurrence," while 71 operations were categorized as persistent disease.
conclusionMany reoperations for papillary thyroid carcinoma are for management of persistent disease. More than half of the patients required reoperation within the first 2 years, which suggests strongly that improvements in the preoperative assessment and adequacy of initial operative therapy need to be made to improve the care of patients with thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.